Aspen Neuroscience, Inc.
NASDAQ · ASPEAspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company developing personalized cell therapies for neurodegenerative diseases. Its platform uses a patient’s own cells to create induced pluripotent stem cell-derived neuronal products, supporting an autologous approach designed to address neurological conditions at the individual level. The company’s lead product candidate, sasineprocel, is an investigational single-dose therapy composed of dopaminergic neuronal precursor cells for Parkinson’s disease. Aspen Neuroscience focuses on advancing cell-based treatments through clinical development, combining stem cell biology, neuroscience, cellular manufacturing, and precision medicine. Its work serves the biopharmaceutical and healthcare sectors, with particular relevance to patients and clinicians seeking alternatives for disorders involving the loss or dysfunction of specific brain cells. Headquartered in San Diego, California, Aspen Neuroscience represents the emerging regenerative medicine segment, where biotechnology companies develop patient-specific therapies intended to replace damaged cells and restore neurological function.
Company profile (no 10-K business section on file)
as of Nov 3, 2026 · today 12.44, 34% of the way from low to high
No dividends on record.
A company that pays none, or whose history has not arrived yet, shows nothing here.
Valuation
Results, trailing twelve months
Balance and cash
Shares and market
Financial statements
Income statement, balance sheet, cash flow, segments
Comps
Valuation, growth and margins against the closest competitors
Filings
Every SEC filing, readable here
Insiders
No sales $68.00M bought · open market, 12 months to Nov 2, 2026
| Insider | Type | Value |
|---|---|---|
| Peter A. ThompsonNov 2, 2026 | Purchase | $15.00M ↗ |
| ORBIMED ADVISORS LLCNov 2, 2026 | Purchase | $15.00M ↗ |
| ARCH Venture Partners XIV, L.P.Nov 2, 2026 | Purchase | $18.00M ↗ |
| ARCH Venture Fund X, L.P.Nov 2, 2026 | Purchase | $1.00M ↗ |
Funds (13F)
No 13F holdings on record
Congress
No trades disclosed
Short interest
No FINRA short interest on record
In the press
No headlines in the business press in the last 30 days.
Company data reported to the SEC on EDGAR (CIK 2124080).
Member research
Everything on ASPE, in full
Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.